nw-301v

Resumen de Ensayos Clínicos

5 ensayos encontrados
Sobre nw-301v

Se está recopilando información detallada sobre este medicamento.

Categoría Otros Medicamentos
5
Total Ensayos
3
Reclutando
1
Activo
0
Completado
80
Inscripción Total
1
Países
Centros activos para nw-301v
Centros reclutando 1 países
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06484556 Fase 1 Reclutando 9 pacientes
Inicio: Jun 2024
Fin: Jun 2027
Intervencional
Medicamentos: NW-301D NW-301V
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
China
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06484790 Fase 1 Reclutando 9 pacientes
Inicio: Apr 2024
Fin: Apr 2027
Intervencional
Medicamentos: NW-301D NW-301V
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
China
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06478251 Fase 1 Reclutando 9 pacientes
Inicio: Feb 2024
Fin: Jun 2027
Intervencional
Medicamentos: NW-301D NW-301V
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
China
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT07474168 Fase 1 Activo 9 pacientes
Inicio: Dec 2025
Fin: Feb 2032
Intervencional
Medicamentos: Nw-301vt
An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor.
China
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
NW-301 TCR-T in Patients With Advanced Solid Tumor
NCT06956261 Fase 1 Aún no recluta 44 pacientes
Inicio: May 2025
Fin: Dec 2027
Intervencional
Medicamentos: NW-301D NW-301V
An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor
China
Ver Detalles ClinicalTrials.gov ¿Soy elegible?
Volver al Glosario Ver Todos los Ensayos Filtrar Reclutando